Accelerating Clinical Trials in the EU (ACT EU)

The Accelerating Clinical Trials in the EU (ACT EU) initiative aims to develop the European Union further as a competitive centre for innovative clinical research. The European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) run the ACT EU initiative together.

ACT EU aims to transform how clinical trials are initiated, designed and run to further promote the development of high quality, safe and effective medicines, and to better integrate clinical research in the European health system.

The initiative seeks to deliver on the clinical trial innovation recommendations of the European medicines agencies network strategy and the European Commission’s Pharmaceutical strategy for Europe.

It builds on the Clinical Trials Regulation (CTR) and Clinical Trials Information System's (CTIS) launch on 31 January 2022.

The European Commission, EMA and Heads of Medicines Agencies (HMA) launched ACT EU in January 2022.

For more information, see the ACT EU website:

How useful was this page?

Add your rating
8 ratings
1 rating